



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61K 31/519* (2006.01)
C07D 473/32 (2006.01) *A61K 31/52* (2006.01)
C07D 487/04 (2006.01) *A61P 3/10* (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:

PCT/IB2013/052404

(22) International Filing Date:

26 March 2013 (26.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/621,144 6 April 2012 (06.04.2012) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).(72) Inventors: **AHN, Kay**; 33 Hill Street, Lexington, Mas-
sachusetts 02421 (US). **BOEHM, Markus**; Fox Avenue,
Fishers Island, New York 06390 (US). **CABRAL, Shawn**;
66 Latham Street, Groton, Connecticut 06340 (US).
CARPINO, Philip A.; 1603 Centre Street, Newton, Mas-

sachusetts 02460 (US). **FUTATSUGI, Kentaro**; 97 West
Main Street, Unit 29, Niantic, Connecticut 06357 (US).
HEPWORTH, David; 282 Sudbury Road, Concord, Mas-
sachusetts 01742 (US). **KUNG, Daniel W.**; 289 Laurel-
wood Drive, Salem, Connecticut 06420 (US). **ORR, Suvi**;
16 Seabreeze Road, Old Saybrook, Connecticut 06475
(US). **WANG, Jian**; 164 White Street, Belmont, Mas-
sachusetts 02478 (US).

(74) Agents: **KLEIMAN, Gabriel L.** et al.; Pfizer Inc., 235
East 42nd Street, New York, NY 10017 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

[Continued on next page]

(54) Title: DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS

FIG. 1




FIG. 1. X-ray powder diffraction pattern of Example 109-B.

(57) **Abstract:** Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))